Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 1

Phase 2

Pepinemab & PembrolizumabPepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Sponsor:

Vaccinex Inc.

Code:

NCT04815720

Conditions

Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

pepinemab + pembrolizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-16. This information was provided to ClinicalTrials.gov by Vaccinex Inc. on 2025-01-08.